This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Adaptimmune (ADAP) Up 7%, Gets T-Cell Programs Rights From GSK
by Zacks Equity Research
Adaptimmune Therapeutics (ADAP) enters into a transition deal with GSK to regain rights to its proprietary T-cell therapy programs. Shares of the company surges 7% following the news.
Horizon's (HZNP) Tepezza Meets Goals in TED Expanded Use Study
by Zacks Equity Research
Horizon Therapeutics (HZNP) announces positive top-line data from its phase IV study of Tepezza to expand its indication to include TED in adult patients with chronic/low clinical activity scores.
Here's Why You Should Add Acadia (ACAD) Stock to Your Portfolio
by Zacks Equity Research
Acadia (ACAD), a top-ranked stock at present, is witnessing steady growth in Nuplazid sales since its launch. The newly approved drug, Daybue, is set to provide an incremental stream of revenues.
Phathom (PHAT) Up 8% on Erosive Esophagitis Drug's CRL Update
by Zacks Equity Research
Phathom Pharmaceuticals (PHAT) announces a regulatory update regarding vonoprazan for the treatment of erosive esophagitis and H. pylori infection. Stock surges 8% following the news.
Seagen's (SGEN) Padcev & Keytruda Combo Gets FDA Accelerated Nod
by Zacks Equity Research
The FDA grants accelerated approval to Seagen (SGEN) and partner, Astellas' combination therapy of Padcev with Merck's Keytruda for the treatment of first and second-line metastatic urothelial cancer.
Apellis (APLS) Kindles Acquisition Interest Per Bloomberg
by Zacks Equity Research
Per a Bloomberg article, Apellis Pharmaceuticals (APLS) is considering a possible buyout by larger pharma companies.
Avidity (RNA) Down on Update From Neuromuscular Disease Study
by Zacks Equity Research
Avidity Biosciences (RNA) provides an update on its phase I/II study of its lead product candidate AOC 1001 for the treatment of myotonic dystrophy type I. The stock falls about 17%.
Adma Biologics (ADMA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adma Biologics (ADMA) delivered earnings and revenue surprises of 14.29% and 1.96%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 5.56% and 41.25%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Mesoblast's (MESO) GVHD Drug BLA Gets FDA Priority Tag, Stock Up
by Zacks Equity Research
Mesoblast (MESO) announces the FDA acceptance for review of the resubmitted biological license application for remestemcel-L for the treatment of children under 12 with steroid-refractory acute graft versus host disease. Stock gains on Wednesday, following the news.
Merck (MRK) Reports Detailed Data From PAH Study on Sotatercept
by Zacks Equity Research
Merck & Co. (MRK) announces detailed data from the phase III STELLAR study of sotatercept for the treatment of pulmonary arterial hypertension in adults.
Seres Therapeutics (MCRB) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -31.71% and 89.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Horizon's (HZNP) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Horizon Therapeutics (HZNP) reports better-than-expected fourth-quarter 2022 results as it beats the Zacks Consensus Estimate for both revenues and earnings.
Intra-Cellular (ITCI) Q4 Earnings & Sales Top, Caplyta Shines
by Zacks Equity Research
Intra-Cellular Therapeutics (ITCI) reports a better-than-expected financial performance in the fourth quarter of 2022 as both earnings and revenues beat estimates.
Allogene (ALLO) Incurs Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Allogene's (ALLO) fourth-quarter earnings beat estimates but sales come in line.
Novavax (NVAX) Q4 Earnings & Revenues Miss Estimates, Stock Down
by Zacks Equity Research
Novavax (NVAX) reports worse-than-expected financial performance in the fourth quarter of 2022, with earnings and revenues both missing the Zacks Consensus Estimate. Stock plunges 26.1% in response to the news.
Acadia (ACAD) Q4 Earnings Miss, Nuplazid Sales Boost Revenues
by Zacks Equity Research
Acadia Pharmaceuticals (ACAD) reports mixed results for the fourth quarter of 2022, recording wider-than-expected loss per share and better-than-expected revenue figures owing to the sales of Nuplazid.
BioMarin (BMRN) Q4 Earnings Miss, Sales Beat, Stock Down
by Zacks Equity Research
BioMarin (BMRN) reports mixed Q4 results as it misses estimates for earnings but beats the same for sales. Its 2023 sales guidance falls short slightly
Seagen (SGEN) Likely to be Acquired by Pfizer Claims WSJ
by Zacks Equity Research
Seagen (SGEN) may be acquired by the large-cap pharma company Pfizer at a valuation of more than $30 billion, according to a Wall Street Journal article. Seagen's stock is up 17% in pre-market hours in response to the news.
Alnylam (ALNY) Q4 Earnings Top, Product Sales Boost Revenues
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) reports better-than-expected fourth-quarter 2022 results. Total revenues of the company continue to be driven by the sales of Onpattro, Givlaari, Oxlumo and the newly approved Amvuttra.
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -50% and 8.29%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
CRISPR (CRSP) Q4 Earnings Surpass Estimates, Sales Miss
by Zacks Equity Research
CRISPR Therapeutics' (CRSP) fourth-quarter 2022 loss is narrower than expected, while sales miss estimates.
Halozyme (HALO) Q4 Earnings Top, Revenues Miss, Stock Down
by Zacks Equity Research
Halozyme Therapeutics (HALO) reports mixed fourth-quarter results. Stock is down in the after-market hours in response to the earnings results.
Blueprint's (BPMC) Q4 Earnings & Sales Top Estimates, Stock Up
by Zacks Equity Research
Blueprint Medicines (BPMC) announces better-than-expected financial performance in fourth-quarter and full-year 2022. Stock up in the aftermarket hours, following the news release.
TEVA Beats Q4 Earnings Estimates, Sales Miss & Stock Down
by Zacks Equity Research
TEVA reports mixed Q4 results, beating earnings estimates, while sales slightly miss estimates. Stock down post earnings release.